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Introduction
The main presentation is shortness of breath 
on exertion. In babies, this may manifest as 
the inability to complete a feed, along with 
an elevated respiratory rate.4
Congenital heart failure
Congenital heart disease leading to heart 
failure in infancy is usually due to a left to 
right shunt inside the heart. This may be 
caused by a hole between the two ventricles 
(ventricular septal defect  - VSD), or a 
persistently patent arterial duct between 
the aorta and the pulmonary artery (patent 
ductus arteriousus – PDA). Since the 
pressures on the left side (all chambers: 
atria, ventricles and aorta) exceed those 
on the right side, blood shunts from left to 
right, flooding the lungs with an excessive 
volume of blood, hence the breathlessness. 
Even at rest, these individuals have a high 
respiratory rate. Lower limb oedema is not 
relevant and not found in this age group.
Because of the physiological way in 
which pressure in the lungs fall after birth, 
large shunts manifest as above, in heart 
failure, at about six weeks of age. Treatment 
of heart failure is usually surgical, at this 
age, but medications are very useful in these 
babies to stabilize and relieve symptoms 
until then.5
Management
Heart failure is initially treated with a 
diuretic to decrease preload by promoting 
natriuresis, and to provide relief of volume 
overload symptoms such as pulmonary 
and peripheral oedema. Loop diuretics are 
used first, usually furosemide. Bumetanide 
is a more potent diuretic and is usually 
reserved for more severe or furosemide-
resistant fluid overload. Furosemide is 
generally supplemented with spironolactone, 
an aldosterone antagonist which reduces 
urinary potassium loss, making it particularly 
suitable for use in conjunction with 
furosemide. In children up to 12 years, 
furosemide is usually prescribed in syrup 
form at a dose of 0.5 - 2 mg, 12 -hourly or 
8-hourly, depending on the patient’s age. 
Spironolactone, is generally prescribed, also 
in syrup form at a dose of 1 - 2 mg /kg/
day in neonates and up to 3 mg/kg/day in 
infants and children up to 12 years; the daily 
dose is given in 1 - 2 divided doses.6
If this is insufficient to control heart 
failure, such that, for example, the baby is 
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Educational aims
•	 To have a better understanding of heart failure in children
•	 To be familiar with the main causes of heart failure in children
•	 To be updated on the treatment of heart failure in this age group
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not thriving well due to the shortness of 
breath, an angiotensin converting enzyme 
inhibitor is added to the treatment. Captopril 
is usually the drug of choice and this is 
generally combined with the loop diuretic 
alone.7
Additional helpful treatment includes 
calorific supplementation of feeds and if 
feeds cannot be taken, babies can be helped 
by nasogastric tube feeding. Naturally, once 
surgery is over, all medications are tailed 
off. A pharmacological issue that often 
arises is that some of these medications may 
not be imported and may be therefore need 
to be extemporaneously prepared by the 
hospital pharmacy.6
Heart failure in older children
Children may also present in heart 
failure acutely at an older age, and the 
commonest cause is viral myocarditis. For 
example, presentation may be a few days 
after a coryzal illness. Treatment is as 
outlined above but the only medication 
which improves long term prognosis is an 
angiotensin converting enzyme inhibitor. If 
not tolerated, e.g. if a dry persistent cough 
develops, an angiotensin receptor blocker 
may be used. A third of these children 
recover completely and their medications are 
stopped. A third recover partially and may 
remain on an angiotensin converting enzyme 
inhibitor. A third will never recover at all, 
developing dilated cardiomyopathy, and may 
remain on treatment until organ replacement 
is arranged. This assumes they survive the 
disease and its complications until a donor 
is found.8
A rarer presentation is that of de-
novo dilated cardiomyopathy which may 
be familial. Treatment is also as outlined 
above.9
Conclusion
All in all, the vast majority of patients with 
heart failure are infants with congenital 
heart disease and fortunately, treatment for 
these patients is available and is excellent 
with very high survival rates.1
Key points
•	 Heart failure is uncommon in childhood but recognition is important.
•	 Commonest causes are congenital heart disease and cardiomyopathy. 
•	 Presentation is tachypnoea and shortness of breath on exertion and poor feeding in 
babies.
•	 The most commonly used drugs are diuretics and angiotensin converting enzyme 
inhibitors.
•	 Calorific supplementation and nasogastric tube feeding may also be required.
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